Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has earned a consensus recommendation of “Buy” from the six analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $9.00.
A number of equities research analysts recently commented on PIRS shares. ValuEngine lowered shares of Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. BidaskClub upgraded shares of Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, HC Wainwright set a $9.00 price target on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 18th.
In related news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $5.70, for a total transaction of $841,519.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.05% of the company’s stock.
Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.12 on Tuesday, hitting $7.55. 705,125 shares of the stock were exchanged, compared to its average volume of 437,069. The company has a market cap of $338.19, a price-to-earnings ratio of -10.20 and a beta of 1.79. Pieris Pharmaceuticals has a 1 year low of $1.38 and a 1 year high of $7.74.
Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $3.93 million during the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The firm’s revenue was up 400.3% on a year-over-year basis. analysts expect that Pieris Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2018/01/01/pieris-pharmaceuticals-inc-pirs-receives-9-00-average-price-target-from-brokerages.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.